Cytoreduction and prognosis in acute lymphoblastic leukemia - The importance of early marrow response: Report from the Childrens Cancer Group

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 389-398

  Steinherz, P G ^a   Gaynon, P S ^a   Breneman, J C ^a   Cherlow, J M ^a   Grossman, N J ^a   Kersey, J H ^a   Johnstone, H S ^a   Sather, H N ^a   Trigg, M E ^a   Chappell, R ^a   Hammond, D ^a   Bleyer, W A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 9044244144     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.389     Document Type: Article

References (47)

1. Frei E: Acute leukemia in children. Cancer 53:2013-2025, 1984
2. Frei E, Karon M, Levin RH, et al: The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26:642-656, 1965
3. Frei E, Sallan SE: Acute lymphoblastic leukemia: Treatment. Cancer 42:828-838, 1978
4. Jacquillat C, Weil M, Gemon MF, et al: Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris). Cancer Res 33:3278-3284, 1973
5. Keating MJ, Smith TL, Gehan EA, et al: Factors related to length of complete remission in adult acute leukemia. Cancer 45:2017-2029, 1980
6. Miller DR, Leikin S, Albo V, et al: Intensive therapy and prognostic factors in acute lymphoblastic leukemia of childhood: CCG-141. A report from Childrens Cancer Study Group, in Neth R, Gallo RC, Graf R, et al (eds): Haematology and Blood Transfusion, vol 26. Modern Trends in Human Leukemia IV. Berlin, Germany, Springer-Verlag, 1981, pp 77-86
7. Trigg ME, Hutchinson R, Lange B, et al: Remission induction of 3,152 children with ALL: Failure and complication rates in CCG studies. Proc Am Soc Clin Oncol 13:321, 1994 (abstr)
8. Hammond D, Sather H, Nesbit M, et al: Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14:124-134, 1986
9. Steinherz PG, Siegel SE, Bleyer WA, et al: Lymphomatous presentation of childhood acute lymphoblastic leukemia: A subgroup at high risk of early treatment failure. Cancer 68:751-758, 1991
10. Steinherz PG, Gaynon P, Miller DR, et al: Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - A new intensive therapy protocol: A report from the Childrens Cancer Study Group. J Clin Oncol 4:744-752, 1986
11. Gaynon PS, Steinherz PG, Bleyer WA, et al: Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Childrens Cancer Group study CCG-106. J Clin Oncol 11:2234-2242, 1993
12. Rivera GK, Pinkel D, Simone JV, et al: Treatment of acute lymphoblastic leukemia. Thirty years' experience at St. Jude Children Research Hospital. N Engl J Med 329:1289-1295, 1993
13. Clavell LA, Gelber RD, Cohen HJ, et al: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
14. Miller DR, Leikin S, Albo V, et al: Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141: A report from the Childrens Cancer Study Group. Cancer 51:1041-1049, 1983
15. Miller DR, Coccia PF, Bleyer WA, et al: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. J Clin Oncol 7:1807-1815, 1989
16. Rivera GK, Raimondi SC, Hancock ML, et al: Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61-66, 1991
17. Gaynon PS, Bleyer WA, Steinherz PG, et al: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273-279, 1990
18. 2). N Engl J Med 308:559-565, 1983
19. Steinherz PG, Gaynon PS, Breneman JC, et al: Treatment of acute lymphoblastic leukemia with lymphomatous features: Report from the Childrens Cancer Group. Med Pediatr Oncol 19:412, 1991 (abstr)
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
22. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
23. Breslow N: Comparison of survival curves, in Buyse M, Staquet M, Sylvester M (eds): Cancer Clinical Trials: Methods and Practice. Oxford, United Kingdom, Oxford University Press, 1988, pp 381-406
24. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
25. Breslow N: Analysis of survival data under the proportional hazards model. Int Stat Rev 43:45-58, 1975
26. Haimi J, Redner A, Steinherz P, et al: Quantitative cytoreduction and cell kinetics during induction therapy in acute lymphoblastic leukemia. Blood 72:202, 1988 (suppl 1, abstr)
27. Steinherz PG, Redner A, Steinherz L, et al: Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The Memorial Sloan-Kettering-New York-II protocol. Cancer 72:3120-3130, 1993
28. Blumenreich MS, Strife A, Clarkson BD: A technique to quantify cytoreduction in the bone marrow induced by cytotoxic chemotherapy. J Clin Oncol 1:552-558, 1983
29. Hiddemann W, Clarkson BD, Buchner T, et al: Bone marrow cell count per cubic millimeter bone marrow: A new parameter for quantitating therapy-induced cytoreduction in acute leukemia. Blood 59:216-225, 1982
30. Mosaoka T, Hasegawa Y, Tatsumi N, et al: On the analysis of decrease curve of leukemic cells during treatment of acute leukemia. Acta Haematol Jpn 39:1-10, 1976
31. Pui C-H, Dodge RK, Dahl GV, et al: Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia. Blood 66:778-782, 1985
32. Rautonen J, Hovi L, Siimes MA: Slow disappearance of peripheral blast cells: An independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia. Blood 71:989-991, 1988
33. Riehm H, Feickert H-J, Schrappe M, et al: Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis, in Buchner T, Schellong G, Hiddemann W, et al (eds): Haematology and Blood Transfusion: Acute Leukemias, vol 30. Berlin, Germany Springer-Verlag, 1987, pp 139-147
34. Feickert HJ, Bettoni C, Schrappe M, et al: Event-free survival of children with T-cell acute lymphoblastic leukemia after introduction of high dose methotrexate in multicenter trial ALL-BFM 86. Proc Am Soc Clin Oncol 12:317, 1993 (abstr 1049)
35. Gajjar A, Ribeiro R, Hancock M, et al: Persistence of circulating blasts after one week of intensive remission induction therapy confers a poor prognosis in childhood acute lymphoblastic leukemia (ALL). Blood 84:515a, 1994 (suppl 1, abstr)
36. Schrappe M, Reiter A, Sauter S, et al: Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukamie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark. Klin Padiatr 206:208-221, 1994
37. Schwarzmeier JD, Paietta E, Mittermayer K, et al: Prediction of response to chemotherapy in acute leukemia by a short-term test in vitro. Cancer 53:390-395, 1984
38. Riccardi R, Lasorella A, Mastrangelo R: Prognostic relevance of clinical pharmacology of antileukemic drugs. Med Pediatr Oncol 14:173-176, 1986
39. Koren G, Ferrazini G, Sulh H, et al: Systemic exposure to mercaptopurine as a prognostic factor in acute lymphoblastic leukemia in children. N Engl J Med 323:17-21, 1990
40. Pieters R, Huismans DR, Loonen AH, et al: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 338:399-403, 1991
41. Pieters R, Kaspers GJL, Klumper E, et al: Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art. Med Pediatr Oncol 22:299-308, 1994
42. Haq R, Sawka CA, Franssen E, et al: Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: A literature review. J Clin Oncol 12:1074-1084, 1994
43. Hutchinson R, Bertolone S, Cooper H, et al: Early marrow response predicts outcome for patients with low-risk ALL: Results of CCG-1881. Proc Am Soc Clin Oncol 13:319, 1994 (abstr 1051)
44. Nachman J, Lukens J, Gaynon P, et al: Predictors of slow early response (SER) to BFM induction therapy in children and young adults with acute lymphoblastic leukemia (ALL). A report from Childrens Cancer Group (CCG). Blood 80:257a, 1992 (suppl 1, abstr 1081)
45. Nachman J, Sather H, Lukens J, et al: Childrens Cancer Group (CCG) study 1882: Augmented BFM (A-BFM) for treatment of children and young adults with high risk acute lymphoblastic leukemia (ALL) showing slow early response (SER). Proc Am Soc Clin Oncol 14:344, 1995 (abstr 1039)
46. Feinstein A, Sosin D, Wells C: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604-1608, 1985
47. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527-537, 1993